Last reviewed · How we verify

Sulfonylurea

Changhua Christian Hospital · FDA-approved active Small molecule ✓ Verified May 2026

Sulfonylurea is a Small molecule drug developed by Changhua Christian Hospital. It is currently FDA-approved. Also known as: SU, Glibenclamide, Gliclazide, Glimepiride.

Sulfonylureas are a class of small molecule organic compounds used in medicine, specifically in the management of diabetes mellitus type 2. They are used to treat type 2 diabetes mellitus, as indicated by various clinical trials registered on ClinicalTrials.gov.

At a glance

Generic nameSulfonylurea
Also known asSU, Glibenclamide, Gliclazide, Glimepiride, Amaryl (glimepiride)
SponsorChanghua Christian Hospital
ModalitySmall molecule
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sulfonylurea

What is Sulfonylurea?

Sulfonylurea is a Small molecule drug developed by Changhua Christian Hospital.

Who makes Sulfonylurea?

Sulfonylurea is developed and marketed by Changhua Christian Hospital (see full Changhua Christian Hospital pipeline at /company/changhua-christian-hospital).

Is Sulfonylurea also known as anything else?

Sulfonylurea is also known as SU, Glibenclamide, Gliclazide, Glimepiride, Amaryl (glimepiride).

What development phase is Sulfonylurea in?

Sulfonylurea is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing